Novartis Partners With Dunad Therapeutics to Develop Protein Degradation Therapies

Novartis has teamed up with Cambridge, UK-based Dunad Therapeutics to develop protein degradation therapies in a deal potentially worth more than $1.3 billion.
Source: Drug Industry Daily